Antiretroviral treatment for HIV infection: Swedish recommendations 2019.
Jaran EriksenChristina CarlanderJan AlbertLeo FlamholcMagnus GisslénLars NavérVeronica SvedhemAylin YilmazAnders SönnerborgPublished in: Infectious diseases (London, England) (2020)
The Swedish Reference Group for Antiviral Therapy (RAV) published recommendations for the treatment of HIV infection in this journal most recently in 2017. An expert group under the guidance of RAV here provides updated recommendations. The most important updates in the present guidelines are the following: (a) The risk of HIV transmission through condomless sex from individuals with fully suppressed HIV viral load is effectively zero. (b) Pre-exposure prophylaxis (PrEP) is recommended for groups with a high risk of HIV infection. (c) Since the last update, two new substances have been registered: bictegravir and doravirine. (d) Dual treatment may be an alternative in selected patients, using lamivudine + dolutegravir or lamivudine + boosted darunavir/atazanavir. As with previous publications, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine. This document does not cover treatment of opportunistic infections and tumours.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- hiv positive
- human immunodeficiency virus
- clinical practice
- end stage renal disease
- stem cells
- men who have sex with men
- randomized controlled trial
- chronic kidney disease
- hepatitis c virus
- ejection fraction
- south africa
- newly diagnosed
- peritoneal dialysis
- combination therapy
- drinking water
- replacement therapy
- patient reported outcomes